Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 20/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.58 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.57 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.48 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828116 | 0.99 | SLC16A1 (0.62) | SLC16A1CYP2C9CYP3A4SLC16A7MAPKAPK2 | |
| SCHEMBL5094497 | 0.98 | SLC16A1 (0.61) | SLC16A1CYP2C9CYP3A4SLC16A7MAPKAPK2 | |
| SCHEMBL5094499 | 0.91 | SLC16A1 (0.60) | SLC16A1CYP2C9CYP3A4SLC16A7MAPKAPK2 | |
| SCHEMBL5100062 | 0.87 | SLC16A1 (0.51) | SLC16A1CYP2C9CYP3A4SLC16A7MAPKAPK2 | |
| SCHEMBL3826720 | 0.86 | SLC16A1 (0.73) | SLC16A1CYP2C9CYP3A4SLC16A7MAPKAPK2 | |
| SCHEMBL3829554 | 0.85 | SLC16A1 (0.74) | SLC16A1CYP2C9CYP3A4SLC16A7MAPKAPK2 | |
| SCHEMBL3826963 | 0.84 | SLC16A1 (0.82) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL3831649 | 0.84 | SLC16A1 (0.82) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL3826712 | 0.84 | SLC16A1 (0.73) | SLC16A1CYP2C9CYP3A4SLC16A7MAPKAPK2 | |
| SCHEMBL3829937 | 0.84 | SLC16A1 (0.75) | SLC16A1CYP2C9CYP3A4SLC16A7MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | C5, TPMT, C9 | SLC16A1 3369/4885CYP2C9 71/4885CYP3A4 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.